Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in XXXX .

@entity5 @entity1 @entity189
AIM: To ascertain pathologic stage as a prognostic indicator for @entity5 @entity1 receiving preoperative chemoradiotherapy (PCRT). METHODS: @entity1 with mid- and low @entity189 (magnetic resonance imaging - based clinical stage II or III) between 2000 and 2009 and treated with curative radical resection were identified. @entity1 were divided into two groups: PCRT and No-PCRT. Recurrence-free survival (RFS) was examined according to pathologic stage and addition of adjuvant treatment. RESULTS: Overall, 894 @entity1 were identified. Of these, 500 @entity1 received PCRT. Adjuvant chemotherapy was delivered to 81.5% of the No-PCRT and 94.8% of the PCRT @entity1 . Adjuvant radiotherapy was given to 29.4% of the @entity1 in the No PCRT group. The 5-year RFS for the No-PCRT group was 92.6% for Stage   I, 83.3% for Stage II, and 72.9% for Stage III. The 5-year RFS for the PCRT group was 95.2% for yp Stage 0, 91.7% for yp Stage   I, 73.9% for yp Stage II, and 50.7% for yp Stage III. CONCLUSION: Pathologic stage can predict prognosis in PCRT @entity1 . 5-year RFS is significantly lower among PCRT @entity1 than No-PCRT @entity1 in pathologic stage II and III. These results should be taken into account when considering adjuvant treatment for @entity1 treated with PCRT.
